Former Chief Financial Officer, Secretary, and Treasurer and Director · Monopar Therapeutics (MNPR)

Kim Tsuchimoto

A named executive officer of Monopar Therapeutics in every fiscal year CompBrief holds from FY2018 to FY2023. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$848,441

Salary $300,000Stock awards $247,219

FY2022: $695,128

3rd of 3 named executive officers at Monopar Therapeutics by FY2023 total.

3 named officers on file for Monopar Therapeutics, FY2023

Kim Tsuchimoto’s pay file — $29

  • 6 fiscal years of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Monopar Therapeutics’s whole pay program stands against its peers

  • Monopar Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on MNPR→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed July 22, 2024 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Kim Tsuchimoto’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Kim Tsuchimoto compensation by year

Monopar Therapeutics Summary Compensation Table · all 6 fiscal years held
In US dollars, as Monopar Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2018FY2019FY2020FY2021FY2022FY2023
Salary$125,991$141,625$218,004$272,100$285,000$300,000
Bonus$2,200$20,000$14,980$0$0$0
Stock awards$0$0$63,654$133,040$172,290$247,219
Option awards$181,046$0$186,411$133,040$172,289$247,221
Non-equity incentive$0$0$40,300$55,700$65,550$54,000
Pension and deferred compensation$0$0$0$0$0$0
All other$18,000$21,600$0$0$0$0
Total$327,237$183,225$523,349$593,880$695,128$848,441

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Monopar Therapeutics DEF 14A filed July 22, 2024, accession 0001437749-24-023123, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Monopar Therapeutics filed document, accession 0001437749-24-023123. Every figure is read from that document and cited to the page and table it appears in. Filed July 22, 2024.

$327K
$183K
$523K
$594K
$695K
$848K
FY18
FY19
FY20
FY21
FY22
FY23
SalaryBonusNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2023 year-end
TypeUnvested unitsValue at year-endExercise price
RSU95,556$32,508—
Option40,697—$2.80
Option6,857—$6.81
Option77,016—$3.16

Per the Outstanding Equity Awards at Fiscal Year-End table in Monopar Therapeutics's FY2023 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

32 Form 4 lines since the FY2023 proxy (filed July 22, 2024)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-11-04Exercise or conversion derivative10b5-1856$0.004,110
2026-11-04Exercise or conversion derivative10b5-12,035$0.006,105
2026-11-04Exercise or conversion10b5-1856$30.00856
2026-11-04Exercise or conversion10b5-12,035$14.002,891
2026-11-04Sale10b5-11,295$70.751,596
2026-11-04Sale10b5-1996$71.35600
2026-11-04Sale10b5-1600$72.210
2026-11-02Exercise or conversion10b5-11,199$30.001,199

The 8 most recent of 32 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Monopar Therapeutics’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Chandler RobinsonChief Executive Officer and Director$1,778,655
Andrew CittadineChief Operating Officer$911,141
Kim Tsuchimoto · this pageFormer Chief Financial Officer, Secretary, and Treasurer and Director$848,441

Board service

Monopar Therapeutics board · FY2023–FY2025
Director compensation in US dollars, as Monopar Therapeutics reports it. Most recent year first; a dash means the company reported no figure in that column.
Fiscal yearCash feesStock awardsOption awardsOtherTotal
FY2025$40,000$0$336,724$13,213$389,937
FY2024$20,000$0$0$0$20,000
FY2023—————

Each year as the company reported it in Monopar Therapeutics's director compensation table. Totals are the company's own disclosed totals.

How this board is paid

Company policy: Monopar Therapeutics pays directors a $40,000 cash retainer. As stated in Monopar Therapeutics's FY2025 proxy.

The full Monopar Therapeutics compensation record

free company brief

This page is one person within Monopar Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Monopar Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Kim Tsuchimoto's compensation dossier · One-time report. No refunds.